Live inventory available for immediate delivery.

NOD Background

  • Model #
  • Genotype
  • Nomenclature
  • HSCFTL-13395-F
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(SV40/HTLV-IL3,CSF2)10-7Jic/JicTac
  • HSCCB-13395-F
    NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(SV40/HTLV-IL3,CSF2)10-7Jic/JicTac
  • Super immunodeficient NOG mouse expressing human GM-CSF and human IL-3 cytokines to support myeloid lineage engraftment
  • Higher overall engraftment levels of human hematopoietic stem cells (HSC) compared to core NOG mouse
  • Higher levels of myeloid cell differentiation following human HSC engraftment compared to core NOG mouse
  • Model of human allergy response
  • Applications in research involving cancer, infectious disease, immunology, regenerative medicine and humanization
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Related Taconic InsightRead the Related Taconic Biosciences' Insight:


hGM-CSF/hIL3 NOG mice engrafted with human CD34+ hematopoietic stem cells (HSCs) stably develop extensive cell lineages as early as 6 to 8weeks post-injection. Both myeloid and lymphoid lineage cells are present in peripheral blood, bone marrow, thymus and spleen and non-lymphoid tissue including lung and liver. Longer term studies are possible in huNOG-EXL mice, with literature reports of stable engraftment and hematopoiesis for at least 20 weeks post engraftment. While, not all human immune cell types have been exhaustively characterized in these mice, extensive myeloid differentiation including granulocyte differentiation (basophil, neutrophil and mast cells) are evident in blood and tissues. Antigen presenting cells (dendritic cells and macrophages) are also increased in frequency, both in blood and spleen.


Taconic maintains an inventory of female huNOG-EXL mice engrafted as juveniles and FACS tested at 10 weeks post-engraftment; in order to ship, all mice must be ≥25% hCD45+ in peripheral blood, but in most cases huNOG-EXL mice average> 40% human cells in blood. Custom options for huNOG-EXL generation are available, such as HLA selection and time of QC and delivery post-engraftment with additional fee.





Initial Publication:

  • Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. (2002) NOD/SCID/γnull/c mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100(9):3175-3182.
  • Fukuchi Y, Miyakawa Y, Kobayashi K, Kuramochi T, Shimamura K, Tamaoki N, Nomura T, Ueyama Y, Ito M. (1998) Cytokine dependent growth of human TF-1 leukemic cell line in human GM-CSF and IL-3 producing transgenic SCID mice. Leuk Res 22(9):837-43.
  • Ito R, Takahashi T, Katano I, Kawai K, Kamisako T, Ogura T, Ida-Tanaka M, Suemizu H, Nunomura S, Ra C, Mori A, Aiso S, Ito M. (2013) Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. J Immunol.191(6):2890-9.

Nonprofit users (excluding users at nonprofit foundations which are affiliated with a for-profit entity): For internal research purposes, the CIEA NOG mouse® Conditions of Use for nonprofit users apply. If you wish to perform sponsored research or fee-for-service contract research using the CIEA NOG mouse®, please inquire for access conditions

For-profit users and users at foundations which are affiliated with for-profit entities: The CIEA NOG mouse® Conditions of Use for for-profit users apply.

Does your research require the use of neonates? Please contact us for more information on neonate access options.

The CIEA NOG mouse® is produced and distributed under license rights to the following patents and trademarks:
  • Japanese Patent No. 3,753,321
  • US Patent No. 7,145,055; 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,789,215; 6,204,061; 6,653,113; 6,689,610
    EP Patent No. 1,338,198
  • Japanese Trademark Reg. No. 4,823,423
  • US Trademark Reg. No. 3,118,040
  • EU Trademark Reg. No. 3,736,758